ePrints

Alchemix: A novel alkylating anthraquinone with potent activity against anthracycline- and cisplatin-resistant ovarian cancer

Lookup NU author(s): Dr Elaine WillmoreORCiD, Professor Caroline AustinORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Chloroethylaminoanthraquinones are described with intercalating and alkylating capacity that potentially covalently cross-link topoisomerase II (topo II) to DNA. These compounds have potent cytotoxic activity (IC50 = 0.9-7.6 nm) against the A2780 human ovarian carcinoma cell line. Hydroxyethylaminoanthraquinones also reported in this paper have similar IC50 values (0.7-1.7 nM) in the same cell line. Alchemix (ZP281M, 1-{2-[N,N-bis(2-chloroethyl)amino]ethylamino}-4-{2-[N,N-(dimethyl)amino]ethylamino}-5,8-dihydroxy-9,10-anthracenedione), an alkylating anthraquinone, retains excellent antitumor activity in Adriamycin-resistant (2780AD) and cisplatin-resistant (2780/cp70) cell lines in vitro and in vivo. This indicates that Alchemix can evade both P-glycoprotein efflux pump and DNA mismatch repair-mediated resistance. In treated cells, Alchemix was shown to preferentially induce drug-stabilized covalent bound topo IIalpha-DNA complexes over topo IIbeta-DNA complexes.

Publication metadata

Author(s): Pors, K., Paniwnyk, Z., Teesdale-Spittle, P., Plumb, J. A., Willmore, E., Austin, C. A., Patterson, L. H.

Publication type: Article

Publication status: Published

Journal: Molecular Cancer Therapeutics

Year: 2003

Volume: 2

Issue: 7

Pages: 607-610

ISSN (print): 1535-7163

ISSN (electronic): 1538-8514

Share